Combination therapy for treating cancer
The disclosure relates to a method for treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and a second agent in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor, e.g., tazemetostat or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods of the disclosure are used to treat breast cancer, ovarian cancer, or both.
1. A method for treating ovarian cancer or breast cancer comprising administering to a subject in need thereof
(a) a therapeutically effective amount of Compound A:
or a pharmaceutically acceptable salt thereof, and
(b) a therapeutically effective amount of a PARP inhibitor selected from iniparib and olaparib.
2. The method of claim 1 , wherein the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is between about 100 mg and about 1600 mg per day, inclusive of the endpoints.
3. The method of claim 1 , wherein the cancer is ovarian cancer.
4. The method of claim 1 , wherein the cancer is breast cancer.
5. The method of claim 1 , wherein Compound A, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor are administered simultaneously.
6. The method of claim 1 , wherein Compound A, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor are administered sequentially.
7. The method of claim 6 , wherein Compound A, or a pharmaceutically acceptable salt thereof, is administered prior to the PARP inhibitor.
8. The method of claim 6 , wherein the PARP inhibitor is administered prior to Compound A, or a pharmaceutically acceptable salt thereof.
9. The method of claim 3 , wherein the ovarian cancer is resistant or refractory to at least one prior monotherapy.
10. The method of claim 4 , wherein the breast cancer is resistant or refractory to at least one prior monotherapy.
11. The method of claim 4 , wherein the breast cancer is estrogen receptor (ER) negative, progesterone receptor (PR) negative, or HER2 negative.
12. The method of claim 4 , wherein the breast cancer is ER negative, PR negative, and HER2 negative.
13. The method of claim 9 , wherein the ovarian cancer is estrogen receptor (ER) negative, progesterone receptor (PR) negative, or HER2 negative.
14. The method of claim 9 , wherein the ovarian cancer is ER negative, PR negative, and HER2 negative.
15. The method of claim 3 , wherein the PARP inhibitor is olaparib.
16. The method of claim 4 , wherein the PARP inhibitor is olaparib.
17. The method of claim 3 , wherein the PARP inhibitor is iniparib.
18. The method of claim 4 , wherein the PARP inhibitor is iniparib.
19. The method of claim 3 , wherein Compound A, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor are administered sequentially.
20. The method of claim 4 , wherein Compound A, or a pharmaceutically acceptable salt thereof, and the PARP inhibitor are administered sequentially.